CTKB Cytek Biosciences Inc.

Biotech Analyst Ratings

Latest News

1. 11 May 2022 Cytek Biosciences Reports First Quarter 2022 Financial Results

   FREMONT, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Cytek^® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB) today reported financial results for the first quarter ended March 31, 2022.
   

   Recent Highlights

   • Total revenue was $35.1 million for the first quarter, representing a 44% increase over the corresponding quarter of 2021
   • Expanded the installed base to 1,226 instruments, with 116 instrument placements during the first quarter
   • Continued to see demand across the increasingly diversified portfolio of Cytek's offerings, including service revenue that has more than doubled from the prior year
     

   "I am pleased with our start to the year, with first quarter revenue growing 44% from the prior year," said Dr. Wenbin Jiang, CEO of…

   View Full Article
2. 28 April 2022 Cytek Biosciences to Report First Quarter Financial Results on May 11, 2022

   FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced it will report financial results for the first quarter 2022 after market close on Wednesday, May 11^th, 2022. The company's management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.
   

   Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com

   About Cytek Biosciences
   Cytek Biosciences is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and…

   View Full Article